According to a market report by Lucintel, the future of the global skin cancer diagnostics & therapeutics market looks promising with opportunities in the diagnosis and therapeutic markets. The global skin cancer diagnostics & therapeutics market is expected to reach an estimated $18 billion by 2030 from $14 billion in 2024, at a CAGR of 5% from 2024 to 2030. The major drivers for this market are increasing government initiatives for early detection and skin cancer treatment, rising research and development activities for skin cancer diagnostics and therapeutics, and growing incidences and rising awareness of skin cancer globally.
A more
than 150-page report to understand trends, opportunity and forecast in global skin
cancer diagnostics & therapeutics market to 2030 by cancer type (melanoma
and non-melanoma), type (diagnosis, therapeutics, and others), and region
(North America, Europe, Asia Pacific, and the Rest of the World).
Lucintel
forecasts that non-melanoma is expected to witness higher growth over the
forecast period due to growing the increasing cases of non-melanoma as these
skin cancer starts in skin cells and a cancerous (malignant) growth is a group
of cancer cells that can grow into and destroy nearby tissue. it can also
spread (metastasize) to other parts of the body, but this is rare with
non-melanoma skin cancer.
Within
this market, therapeutic will remain the largest segment.
Download
sample by clicking on skin
cancer diagnostics & therapeutics market.
North
America will remain the largest segment over the forecast period due to the
growing prevalence and incidence of skin cancers in this region.
Ab
Science, Abbott Laboratories, Amgen, Astrazeneca, Bristol-Myers Squibb, Castle
Biosciences, Daiichi Sankyo, Damae Medical, Dermtech, F. Hoffmann-La Roche are
the major suppliers in the skin
cancer diagnostics & therapeutics market.
This unique research
report will enable you to make confident business decisions in this globally
competitive marketplace. For a detailed table of contents, contact Lucintel at
+1-972-636-5056 or write us at helpdesk@lucintel.com. To get access of more than 1000 reports at fraction of cost
visit Lucintel's Analytics
Dashboard.
About Lucintel
At Lucintel, we offer solutions for
you growth through game changer ideas and robust market &
unmet needs analysis. We are based in
Dallas, TX and have been a trusted advisor for 1,000+ clients for over 20
years. We are quoted in several publications like the Wall Street Journal,
ZACKS, and the Financial Times.
Contact:
Roy Almaguer
Lucintel
Dallas, Texas, USA
Email: roy.almaguer@lucintel.com
Tel. +1-972-636-5056
Explore Our Latest Publications
Hazardous Drug Compounding System Market
Intelligent Outbound Call Center Market
Omnichannel Call Center Service Market
No comments:
Post a Comment